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ASICs (acid-sensing ion channels) are proton-gated channels that are important for pain sensation. Newwork
by Yu and coworkers in this issue of Neuron identifies synthetic ligands and related small molecules found
in the inflammatory soup that activate ASICs. These new findings highlight the power of small molecule
screening to find new compounds that can control channel function. They also demonstrate how the
discovery and characterization of such molecules can lead to new insights regarding channel mechanism
and natural ligands.Acidification of extracellular fluid hurts
and is a common consequence of injury,
inflammation, and ischemia. Even though
protons are a general component of
aqueous solutions and all proteins carry
elements that are titratable, the promi-
nence of extracellular acidosis in injury
has driven the idea that organisms might
have a dedicated ‘‘receptor’’ for detecting
extracellular pH changes (Krishtal, 2003).
The leading candidate molecules for
such a role are a set of transmembrane
proteins known as acid-sensing ion
channels (ASICs). These molecules are
voltage independent, sodium selective,
proton-gated ion channels that belong
to a larger family of epithelial sodium
channel/degenerin (ENaC/DEG) channels
(Wemmie et al., 2006).
ASICs are exceptionally sensitive to
changes in extracellular proton concen-
tration, having a Hill coefficient of 6-8
(Jasti et al., 2007; Krishtal, 2003). Tissue
acidosis accompanies pain, inflamma-
tion, and hyperalgesia and in the brain is
associated with ischemia and neuronal
injury. Because ASICs appear to be
primed to respond to such changes,
they are leading targets for the develop-
ment of novel compounds that could be
used to control pain or that might be
effective to treat ischemic brain injury
(Sluka et al., 2009; Xiong et al., 2008).
Nevertheless, there has remained a
lingering question regarding whether the
pH changes to which the channel is soexquisitely sensitive happen in native
settings (Wemmie et al., 2006). This ques-
tion, together with the notably large extra-
cellular domain present in each channel
subunit, has fueled the hypothesis that
ASICs might be sensitive to naturally
occurring ligands other than protons
(Wemmie et al., 2006).
The notable functional signature of
ASIC activation by protons is a rapid
activation of the channel followed by
a fast desensitization. The precise mech-
anistic details of how ASICs gate remain
unknown. Recent high-resolution crystal-
lographic structural studies of what is
likely to be a desensitized conformation
of ASIC1 have revealed a pocket enriched
in acidic residues that is part of the pH
sensor (Gonzales et al., 2009; Jasti et al.,
2007; Figure 1A). It is in this context, that
the new work by Xu and colleagues (Yu
et al., 2010) makes an exciting new step
in the development of ASIC chemical
biology that bridges biophysical studies
of the channel with functional studies of
the discovered compounds in an authen-
tic physiological setting.
Similar to many other ion channel
families, the pharmacological toolkit that
can be used for specific manipulation of
ASICs is limited (Deval et al., 2010; Krish-
tal, 2003; Xiong et al., 2008). There are
only two high-affinity, selective ASIC
inhibitors known. Both are venom-derived
peptides, one from a tarantula, psalmo-
toxin 1, and the other, APETx2, fromNeurona sea anemone (Diochot et al., 2007).
Psalmotoxin 1 acts as a potent analgesic
(Mazzuca et al., 2007). This impressive
physiological result highlights the power
that selective ASIC modulators have to
help dissect the underlying biology of
the channel and suggests possible start-
ing points for new pain-directed thera-
peutics (Deval et al., 2010; Sluka et al.,
2009; Xiong et al., 2008). Although these
peptides have been very useful tools
other types of modulators are very much
needed.
Xu and colleagues set out to find small
molecules that could modify the activity
of ASIC3, an ASIC that is particularly
important for inflammatory pain (Deval
et al., 2008). One of the major barriers
to small molecule based exploration of
ion channel chemical biology is that the
available functional assays, such as
standard whole cell electrophysiological
recording, are not adept at processing
the large numbers of candidate molecules
(10,000–1,000,000) that are generally
used for screening campaigns (Dunlop
et al., 2008). To circumvent this limitation,
Xu and colleagues exploited the structural
information, focused on screening a
library of 300 molecules bearing basic
moieties, and were motivated by the
idea that such molecules might interact
with the functionally important acidic
regions of the extracellular domains. This
strategy was important as it limited the
candidate molecules to a set that could68, October 7, 2010 ª2010 Elsevier Inc. 1
Figure 1. ASIC Structure, Modulators, and Sites of Action
(A) Structure of ASIC1 (3HGC) (Gonzales et al., 2009). Conserved acidic pairs in the putative proton sensing pocket and those that affect GMQ action are shown
in yellow and red. Putative proton sensing pocket and the site of GMQ covalent modification are shown. Extracellular and membrane-spanning regions are
indicated.
(B) Chemical structures of GMQ, agmatine, arcaine, and amiloride.
(C) Close-up of the positions of the conserved Glu79 and Glu423 residues. The structure is from ASIC1. The labels correspond to the ASIC3 numbering.
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physiology. The authors identified a
molecule, GMQ (2-guanidine-4-methyl-
quinazoline), that evokes large ASIC3
currents and that unlike proton-evoked
currents show little or no desensitization.
GMQ contains a guanidinium moiety
attached to an aromatic scaffold (Fig-
ure 1B). By following a classic ‘‘struc-
ture-activity relationship’’ (SAR) approach
that assayed the functional effects of
changes in specific regions of the GMQ
scaffold, the authors show that even
though the potency of GMQ is not excep-
tionally high (EC50350 mM), the series of
GMQ related derivatives show character-
istics that suggest specific interactions
with the channel.
The initial expectation was that GMQ,
which bears a guanido group, would
target the proton-sensing, acidic residue
rich pocket. However, mutational analysis
suggests that this is not the case asmuta-
tions in the acidic-rich pocket that affect
pH sensing spare the GMQ response.
Further tests for residues affecting GMQ
action identified two key acidic residues
that lie in the subunit-subunit interface
(Figure 1C) at a position that is nearer to
the membrane than the proton-sensing
site (Figure 1A). Previous studies had
shown that substitution of one of these2 Neuron 68, October 7, 2010 ª2010 Elsevierpositions with cysteine, E79C, resulted
in ASIC3 channels that could be modified
in a state dependent manner by a variety
of thiol reactive agents (Cushman et al.,
2007). Further, E79C modification slowed
desensitization substantially. Making
use of these observations, the authors
examined the classic thiol modifying Ell-
man’s reagent (5, 50-dithiobis(2-nitroben-
zoic acid), DTNB) as well as a DTNB-like
GMQ derivative that could also act as
a thiol exchange reagent. Strikingly, both
activated the channel by covalent modifi-
cation of E79C. This action, in the context
of the structural data, is consistent with
the idea that there is some type of confor-
mational change in the subunit-subunit
interfaces in the region of E79, as the
conserved E79 equivalent in ASIC1 is
not accessible in the desensitized struc-
tures and buried in the subunit-subunit
interface.
Although the data point to the impor-
tance of E79 for activation by GMQ, the
question of whether the interaction is
direct remains unresolved. The simplest
explanation in which the effect would
involve a direct interaction between the
E79 carboxylate and the GMQ guanido
group does not appear to be satisfactory.
Replacement of the E79 acidic side
chain with a 5-thio-2-nitrobenzoic acidInc.(TNB) activates the channel. This effect
depends on the presence of the carbox-
ylate and happens in the absence of
an obvious exogenous positive counter-
charge. Additionally, the portion of the
disulfide linked GMQ that reacts with
E79C is at the opposite end of the mole-
cule from the guanido group. Thus, the
mode of activation of the covalent GMQ
may be different from that of GMQ alone.
Nevertheless, the data support the idea
that the essential factor for activation
is a structural rearrangement at the
subunit-subunit interface. Regardless of
the actual mechanism, several lines of
evidence, such as nonoverlapping sen-
sors for H+ and GMQ and differences in
the activation kinetics support the idea
that GMQ activation is different from
proton-based activation. Further, the two
mechanisms do not appear to be inde-
pendent as changes in pH dramatically
alter the response of the channel to
GMQ. Together, these results hint at the
possibility that the two interactive modes
of activation may have physiological
relevance.
The activity of GMQ prompted Yu et al.
(2010) to look for natural molecules having
similar chemical structures that might
act as endogenous ligands. This search
showed that two guanido-containing
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are byproducts of arginine metabolism
(Regunathan, 2006), also cause persistent
ASIC3 activation. Although these com-
pounds are less effective than GMQ, the
observation that naturally occurring mole-
cules that may be present at sites of
inflammation affect ASIC function raises
the possibility that natural ligands such
as these may be involved in the normal
functioning of the channel. In support of
these ideas, both GMQ and agmatine
injection elicit pain-induced paw licking
that is diminished in ASIC3 knockout
mice and that is antagonized by the
nonspecific ASIC blocker amiloride (Deval
et al., 2010; Xiong et al., 2008). Impor-
tantly, the pain-induced behavior caused
by GMQ follows the biophysical SAR
studies and provides further support that
the measured effects are mediated via
ASICs.
Together, the new Yu et al. (2010)
studies provide an elegant example of
the power of small molecule based ion
channel screens to identify novel channel
modulators. They further demonstrate
that such molecules can have great utility
for probing channel mechanisms of action
and for developing ideas about the effects
of naturally occurring ligands. Many ques-
tions remain. How many GMQ molecules
does it take to activate the channel?
What are the determinants that make
GMQ, arcaine, and agmatine specific for
ASIC3 over the other ASICs? Are agma-
tine and arcaine, which are both better
known for suppressing, not causing pain
responses (Regunathan, 2006), the natu-
ral ligands? Are there other endogenous
amines released by inflamed tissue thatwill activate ASICs and act with a much
greater potency? Amiloride, which as
has a structure that has features similar
to the activators (Figure 1B), is an inhib-
itor. Whether its site of action is the
same as GMQ is not known.
The presence of a reactive cysteine
that can be modified to affect channel
behavior may provide a very useful handle
for further advances toward each of these
questions. Thiol-capture strategies have
proven very effective for identifying and
improving novel modulators of soluble
proteins (Erlanson et al., 2004). The clear
sensitivity of the E79C mutant to thiol
exchange compounds suggests that
such strategies could provide a facile
way forward for further elaboration of
ASIC modulators. Additionally, the dra-
matic effect of E79C covalent modifica-
tion may provide a means for trapping
an ASIC channel open state for structural
studies. The development of potent
pharmacological tools for ion channels
remains an arduous task (Dunlop et al.,
2008). The work by Xu and colleagues
nicely demonstrates how the interplay
between structure-directed approaches,
functional studies, and classic SAR can
discover new compounds and uncover
unexpected facets of ion channel mecha-
nism and functional biology.ACKNOWLEDGMENTS
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